Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study

被引:108
作者
Kreutz, Rolf P. [2 ,3 ]
Stanek, Eric J. [1 ]
Aubert, Ronald [1 ]
Yao, Jianying [1 ]
Breall, Jeffrey A. [3 ]
Desta, Zeruesenay [2 ]
Skaar, Todd C. [2 ]
Teagarden, J. Russell [1 ]
Frueh, Felix W. [1 ]
Epstein, Robert S. [1 ]
Flockhart, David A. [2 ]
机构
[1] Medco Hlth Solut Inc, Dept Med & Analyt Affairs, Franklin Lakes, NJ 07417 USA
[2] Indiana Univ, Sch Med, Div Clin Pharmacol, Indianapolis, IN USA
[3] Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA
来源
PHARMACOTHERAPY | 2010年 / 30卷 / 08期
基金
美国国家卫生研究院;
关键词
clopidogrel; proton pump inhibitor; PPI; myocardial infarction; stroke; catheterization; stents; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOGENOMICS; LANSOPRAZOLE; OMEPRAZOLE; RISK;
D O I
10.1592/phco.30.8.787
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To investigate the potential impact of proton pump inhibitors (PPIs) on the effectiveness of clopidogrel in preventing recurrent ischemic events after percutaneous coronary intervention (PCI) with stent placement. Design. Population-based, retrospective cohort study. Data Source. National medical and pharmacy benefit claims database comprising approximately 19 million members. Patients. A total of 16,690 patients who had undergone PCI with stent placement and who were highly adherent to clopidogrel therapy alone (9862 patients) or to clopidogrel with a PPI (6828 patients) between October 1, 2005, and September 30, 2006. Measurements and Main Results. The primary end point was the occurrence of a major adverse cardiovascular event during the 1.2 months after stent placement. These events were defined as hospitalization for a cerebrovascular event (stroke or transient ischemic attack), an acute coronary syndrome (myocardial infarction or unstable angina), coronary revascularization (PCI or coronary artery bypass graft), or cardiovascular death. A composite event rate was compared between patients who received clopidogrel alone and those who received concomitant clopidogrel-PPI therapy. Baseline differences in covariates were adjusted by using Cox proportional hazards models. In the 9862 patients receiving clopidogrel alone, 1766 (17.9%) experienced a major adverse cardiovascular event compared with 1710 patients (25.0%) who received concomitant clopidogrel-PPI therapy (adjusted hazard ratio 1.51, 95% confidence interval 1.39-1.64, p<0.0001). Similar associations of increased risk were observed for each PPI studied (omeprazole, esomeprazole, pantoprazole, and lansoprazole). Conclusion. Concomitant use of a PPI and clopidogrel compared with clopidogrel alone was associated with a higher rate of major adverse cardiovascular events within 1 year after coronary stent placement.
引用
收藏
页码:787 / 796
页数:10
相关论文
共 25 条
[1]   ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents [J].
Bhatt, Deepak L. ;
Scheiman, James ;
Abraham, Neena S. ;
Antman, Elliott M. ;
Chan, Francis K. L. ;
Furberg, Curt D. ;
Johnson, David A. ;
Mahaffey, Kenneth W. ;
Quigley, Eamonn M. .
CIRCULATION, 2008, 118 (18) :1894-1909
[2]  
Bhatt DL., 2009, TRANSC CARD THER TCT
[3]  
*COG PHARM, CLOP OPT GASTR EV CO
[4]   Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study [J].
Collet, Jean-Philippe ;
Hulot, Jean-Sebastien ;
Pena, Anna ;
Villard, Eric ;
Esteve, Jean-Baptiste ;
Silvain, Johanne ;
Payot, Laurent ;
Brugier, Delphine ;
Cayla, Guillaume ;
Beygui, Farzin ;
Bensimon, Gilbert ;
Funck-Brentano, Christian ;
Montalescot, Gilles .
LANCET, 2009, 373 (9660) :309-317
[5]   Clinical significance of the cytochrome P4502C19 genetic polymorphism [J].
Desta, Z ;
Zhao, XJ ;
Shin, JG ;
Flockhart, DA .
CLINICAL PHARMACOKINETICS, 2002, 41 (12) :913-958
[6]  
Dunn SP, 2008, CIRCULATION, V118, pS815
[7]   Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations [J].
Ellis, Kyle J. ;
Stouffer, George A. ;
McLeod, Howard L. ;
Lee, Craig R. .
PHARMACOGENOMICS, 2009, 10 (11) :1799-1817
[8]   Pharmacogenomics of proton pump inhibitors [J].
Furuta, T ;
Shirai, N ;
Sugimoto, M ;
Ohashi, K ;
Ishizaki, T .
PHARMACOGENOMICS, 2004, 5 (02) :181-202
[9]   Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin [J].
Gilard, Martine ;
Arnaud, Bertrand ;
Cornily, Jean-Christophe ;
Le Gal, Gregoire ;
Lacut, Karine ;
Le Calvez, Genevive ;
Mansourati, Jacques ;
Mottier, Dominique ;
Abgrall, Jean-Francois ;
Boschat, Jacques .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (03) :256-260
[10]   Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome [J].
Ho, P. Michael ;
Maddox, Thomas M. ;
Wang, Li ;
Fihn, Stephan D. ;
Jesse, Robert L. ;
Peterson, Eric D. ;
Rumsfeld, John S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (09) :937-944